InvestorNewsBreaks – Pressure BioSciences Inc.’s (PBIO) Scalable UST(TM) Process Shown to Create Rock-Solid 18-Month Stability

Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and innovative services to the worldwide biotechnology, biotherapeutics, cosmetics, nutraceuticals, agrochemical, and food and beverage industries. The company today announced that hemp-derived cannabidiol (“CBD”) processed with its patented Ultra Shear Technology(TM) (“UST(TM)”) platform produced high-quality water-soluble nanoemulsions of CBD oil in water that have demonstrated rock-solid visual and analytical stability 18 months after production and baseline testing. “Nanoemulsions, liposomes and solid lipid nanoparticles present many exciting opportunities as pharmaceutical and nutraceutical delivery systems. The smaller the size of oil droplets or particles, the better the stability and bioavailability of these preparations,” said PBI Chief Science Officer Dr. Alexander V. Lazarev. “Once the droplets/particles reach below about 100 nanometers, nanoemulsions appear optically clear and remain stable for months or even years, thus maintaining their aesthetic appeal, bioavailability and, importantly, their shelf life. Moreover, these preparations can be filter-sterilized to comply with FDA requirements for injectable drugs. Today we are pleased to announce that our enabling, affordable and scalable UST process has been shown to create nanoemulsions that maintain rock-solid stability, excellent water solubility, and pristine visual clarity at room temperature for at least 18 months. These results offer the potential to significantly increase shelf life and effectiveness for CBD and a multitude of other oil-based products in use today.”

To view the full press release, visit https://ibn.fm/pNqUN

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.